TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11481402

Group type: EXPERIMENTAL
Intervention: Touchi-extract (TE) 0.3 g before each meal for 3 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (Houji-tea without TE)
Number of subjects: 36
Study: 9951916

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) 5 MU TIW SQ for 6 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Desferrioxamine infused at a dose of 80 mg/kg per cycle
Number of subjects: 40
Study: 7850395

Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Unilateral ECT
Number of subjects: 140

Group type: COMPARATOR
Intervention: Normal EEG
Number of subjects: 140

Group type: COMPARATOR
Intervention: Abnormal EEG
Number of subjects: 140
Study: 2853753

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg once a day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1841828

Group type: EXPERIMENTAL
Intervention: Phenobarbital (20 mg/kg loading dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study: 594674

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (total dose of 3,300 rads in 3 weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nephrectomy-only (control group)
Number of subjects: 88
Study: 31489842

Group type: EXPERIMENTAL
Intervention: Personalized prompts via mHealth app
Number of subjects: 69
Study: 28142202

Group type: EXPERIMENTAL
Intervention: Deferasirox film-coated tablet (FCT)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Deferasirox dispersible tablets (DT)
Number of subjects: 173
Study: 26313463

Group type: COMPARATOR
Intervention: D1 dissection group
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: D2 dissection group
Number of subjects: 1078

Group type: COMPARATOR
Intervention: D1 group with major non-compliance
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: D2 group with major non-compliance
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: D2 compliant + contaminated group
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: D2 contaminated group
Number of subjects: 1078
Study: 24010675

Group type: EXPERIMENTAL
Intervention: LY2196044 (125 or 250 mg/d)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 20941459

Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg bid, 10 mg bid or 20 mg qd)
Number of subjects: 520

Group type: COMPARATOR
Intervention: LMWH/VKA
Number of subjects: 520
Study: 18583436

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA supplements
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 17485157

Group type: EXPERIMENTAL
Intervention: Social rejection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social acceptance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Defensiveness as a moderating factor
Number of subjects: 0
Study: 15164169

Group type: EXPERIMENTAL
Intervention: Acarbose treatment
Number of subjects: 61
Study: 11441409

Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m(2) plus cisplatin 75 mg/m(2) every 3 weeks
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m(2) plus carboplatin to an area under the curve of 6 mg/mL x min every 3 weeks
Number of subjects: 1220

Group type: COMPARATOR
Intervention: vinorelbine 25 mg/m(2) weekly plus cisplatin 100 mg/m(2) monthly
Number of subjects: 1220
Study: 9608923

Group type: EXPERIMENTAL
Intervention: Hemisynthesis diosmine 600 mg, one tablet per day taken in the morning
Number of subjects: 255

Group type: COMPARATOR
Intervention: Usual tablet formulation of diosmine 300 mg taken twice a day (morning and evening)
Number of subjects: 255
Study: 8001524

Group type: EXPERIMENTAL
Intervention: 60 mg retinol as retinyl palmitate every 4 months for 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo) not specified
Number of subjects: 0
Study: 2648213

Group type: EXPERIMENTAL
Intervention: Acyclovir, 800 mg 5 times daily for 7 days
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 30366387

Group type: EXPERIMENTAL
Intervention: Total Worker Health® program, 'All the Right Moves'
Number of subjects: 607
Study: 27941961

Group type: EXPERIMENTAL
Intervention: Bipolar coagulation forceps
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 527

Group type: COMPARATOR
Intervention: Conventional thyroidectomy
Number of subjects: 527
Study: 24557659

Group type: EXPERIMENTAL
Intervention: 99mTc-antimony sulfide colloid (ASC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 99mTc-filtered sulfur colloid (FSC)
Number of subjects: 24
Study: 22093096

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide (TAC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) tattooing
Number of subjects: 40
Study: 20217150

Group type: EXPERIMENTAL
Intervention: Gabapentin 200 mg and imipramine 10 mg every 12 h orally (G400-I group)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Gabapentin 200 mg every 12 h orally (G400 group)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg every 12 h orally (G800 group)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Imipramine 10 mg every 12 h orally (I group)
Number of subjects: 52
Study: 18936501

Group type: EXPERIMENTAL
Intervention: NPL insulin
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 116
Study: 16048153

Group type: EXPERIMENTAL
Intervention: Vibraject (vibrating dental local anesthesia attachment)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (standard injection without Vibraject)
Number of subjects: 10
Study: 12443742

Group type: EXPERIMENTAL
Intervention: Minimally invasive direct aortic surgery (MIDAS)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional aorto-bifemoral by-pass surgery
Number of subjects: 300
Study: 10100064

Group type: EXPERIMENTAL
Intervention: Self-measurement (SM) using an OMRON HEM706 oscillometric device
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups received additional perindopril or indapamide
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Self-measurement (SM)
Number of subjects: 62
Study: 8889438

Group type: EXPERIMENTAL
Intervention: E25 (Estraderm 25)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: E50 (Estraderm 50)
Number of subjects: 71
Study: 2006119

Group type: EXPERIMENTAL
Intervention: Combination of intramuscular polyestradiol phosphate (PEP) and oral ethinyl estradiol
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Intramuscular PEP alone
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Orchiectomy
Number of subjects: 477

Group type: COMPARATOR
Intervention: Finnish male population (control group)
Number of subjects: 477
Study: 6332893

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (twice daily for 6 months)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (for 6 months)
Number of subjects: 37
Study: 31859575

Group type: EXPERIMENTAL
Intervention: Biological mesh (Veritas®)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Synthetic mesh (TIGR® Matrix Surgical Mesh)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both biological and synthetic meshes
Number of subjects: 15
Study: 28940481

Group type: EXPERIMENTAL
Intervention: Pessary (Bioteque cup pessary)
Number of subjects: 122

Group type: COMPARATOR
Intervention: No pessary
Number of subjects: 122
Study: 27422600

Group type: EXPERIMENTAL
Intervention: Individualised directional preference management plus guideline‐based advice
Number of subjects: 78

Group type: COMPARATOR
Intervention: Advice alone
Number of subjects: 78
Study: 25376862

Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 901

Group type: COMPARATOR
Intervention: In-person counseling
Number of subjects: 901
Study: 22137185

Group type: EXPERIMENTAL
Intervention: SPARX computerized Cognitive Behavioural Therapy (cCBT) completed over 5 weeks (n=20)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waitlist control (n=12)
Number of subjects: 32
Study: 19770739

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP) therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard therapy (without IABP)
Number of subjects: 45
Study: 18030086

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Combination of fluoxetine and CBT
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Parents
Number of subjects: 439
Study: 16275871

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 5804

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5804
Study: 12042265

Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone orally followed by 800 microg vaginal misoprostol
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo followed by 800 microg vaginal misoprostol
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol regimen
Number of subjects: 250
Study: 10084721

Group type: EXPERIMENTAL
Intervention: Repetitive discharges (RDs) observed in lower motor neuron lesions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amplitude of the second component of RDs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Jitter of the components of RDs
Number of subjects: 0
Study: 7570567

Group type: EXPERIMENTAL
Intervention: Adrenaline (0.1 microgram/kg/min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amrinone (bolus 1 mg/kg, continuous infusion of 5‐10 micrograms/kg/min)
Number of subjects: 20
Study: 2160667

Group type: EXPERIMENTAL
Intervention: Intensive combined chemotherapy (B)
Number of subjects: 99

Group type: COMPARATOR
Intervention: High-dose half-body irradiation (HBI) (A)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Local or locoregional radiotherapy (C)
Number of subjects: 99
Study: 6448131

Group type: EXPERIMENTAL
Intervention: Topical 1 percent clindamycin phosphate (Cleocin T)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral tetracycline 500 mg/day
Number of subjects: 50
Study: 30826273

Group type: EXPERIMENTAL
Intervention: Stem-cell transplantation
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 228

Group type: COMPARATOR
Intervention: High minimal residual disease
Number of subjects: 228

Group type: COMPARATOR
Intervention: Low minimal residual disease
Number of subjects: 228
Study: 27513532

Group type: EXPERIMENTAL
Intervention: Nurse‐led, goal‐directed sedation protocol
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1157
Study: 26267721

Group type: EXPERIMENTAL
Intervention: 2% tofacitinib
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 0.2% tofacitinib
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 0.02% tofacitinib
Number of subjects: 81

Group type: COMPARATOR
Intervention: Vehicle solution
Number of subjects: 81
Study: 23537750

Group type: EXPERIMENTAL
Intervention: Split-dose sodium picosulphate/magnesium oxide/anhydrous citric acid (Citrafleet(®)) regimen administered 2 to 6 hours before colonoscopy
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Split-dose sodium picosulphate/magnesium oxide/anhydrous citric acid (Citrafleet(®)) regimen
Number of subjects: 193
Study: 21323461

Group type: EXPERIMENTAL
Intervention: Comprehensive posthospitalization nurse-led interdisciplinary care management
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Standardized, evidence-based medical and psychosocial intervention protocols
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Chronic illness management intervention
Number of subjects: 530
Study: 19118083

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg twice daily for 9 days, coadministered with a single 5‐mg dose of fingolimod on the 4th day of ketoconazole treatment.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fingolimod 5 mg single dose in period 1 without ketoconazole.
Number of subjects: 22
Study: 17552958

Group type: EXPERIMENTAL
Intervention: 1-day frequency-volume chart (FVC)
Number of subjects: 140
Study: 16734123

Group type: EXPERIMENTAL
Intervention: Serum sICAM‐1 levels in chronic HCV patients
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Serum sICAM‐1 levels in NBNC-CLD patients
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels in HCV-RNA positive patients
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels correlation with ALT
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels correlation with AST
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels correlation with prothrombin time
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels correlation with alkaline phosphatase
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels correlation with albumin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels correlation with clinical findings in chronic HCV patients
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels and Knodell score
Number of subjects: 57
Study: 11223701

Group type: COMPARATOR
Intervention: First trimester pregnant women
Number of subjects: 30

Group type: COMPARATOR
Intervention: Third trimester pregnant women
Number of subjects: 30
Study: 9599555

Group type: EXPERIMENTAL
Intervention: Cardioselective beta 1 antagonists for more than three months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (never received beta-blockers)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cardioselective beta 1 antagonists
Number of subjects: 40
Study: 9208342

Group type: EXPERIMENTAL
Intervention: 100 micrograms cerivastatin as a 1-minute bolus infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 micrograms cerivastatin orally as tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: 200 micrograms cerivastatin as an oral solution
Number of subjects: 12
Study: 1901072

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 270

Group type: COMPARATOR
Intervention: Recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 270
Study: 7119508

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 96.6 and 135 million units of human interferon-alpha over 12-15 weeks
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intralesional injections of human interferon-alpha (double blind, placebo-controlled)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intralesional injections of human interferon-alpha
Number of subjects: 2
Study: 31094879

Group type: EXPERIMENTAL
Intervention: Body weight supported treadmill training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 40
Study: 27622387

Group type: EXPERIMENTAL
Intervention: Citalopram (30 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Galantamine (8 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 26085028

Group type: EXPERIMENTAL
Intervention: Insulin glargine/glulisine once daily
Number of subjects: 335

Group type: COMPARATOR
Intervention: Biphasic insulin aspart/aspart protamine 30/70 twice daily
Number of subjects: 335
Study: 24574939

Group type: EXPERIMENTAL
Intervention: Double J stent insertion
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 53
Study: 22473780

Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) with a 25 ms interval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous transcranial direct current stimulation (TDCS; 2 mA) over the cerebellum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) with a 21.5 ms interval
Number of subjects: 0
Study: 19175979

Group type: EXPERIMENTAL
Intervention: Ziprasidone (80 to 160 mg/day)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Risperidone (6 to 10 mg/day)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 139

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 139
Study: 17156266

Group type: EXPERIMENTAL
Intervention: 20 mg of D‐amphetamine + physiotherapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 100 mg of L‐dopa + physiotherapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 10 mg of D‐amphetamine + 50 mg of L‐dopa + physiotherapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo + physiotherapy
Number of subjects: 25
Study: 15669780

Group type: EXPERIMENTAL
Intervention: Diabetes Management Scale
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Mismanagement of insulin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Eating 3 meals a day, getting insulin every day, and more assistance with meals
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Racial/Ethnic Comparison
Number of subjects: 31
Study: 12057081

Group type: EXPERIMENTAL
Intervention: Selective serotonin re‐uptake inhibitors (SSRIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9336420

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA) + Methotrexate (MTX) for 48 weeks (group 1)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Cyclosporine (CSA) + Methotrexate (MTX) for 24 weeks (group 2)
Number of subjects: 92
Study: 16350565

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/day
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study: 3542323

Group type: EXPERIMENTAL
Intervention: 60 mg sustained‐release furosemide preparation (FR)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 mg standard furosemide tablet (F)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 12
Study: 29724115

Group type: COMPARATOR
Intervention: Virtual control group created using an algorithm based on integrated data from RCTs.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment group from two archived randomized control trials (RCTs) assessing intentions, normative beliefs, values, and substance use.
Number of subjects: 0
Study: 27855660

Group type: COMPARATOR
Intervention: Fentanyl 2 mcg/kg (Group F)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.2 mg/kg (Group O)
Number of subjects: 64
Study: 25164220

Group type: EXPERIMENTAL
Intervention: Sequential combination therapy (iloprost: 10 µg/inhalation, 6 times per day for 6 months, then add oral tadalafil (5 mg/d) till 12 months, n = 32)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Upfront combination therapy (iloprost: 10 µg/inhalation, 6 times per day combined with oral tadalafil (5 mg) for 12 months, n = 36)
Number of subjects: 72
Study: 22613154

Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP) + Ketorolac
Number of subjects: 22
Study: 20051917

Group type: EXPERIMENTAL
Intervention: PCM arthroplasty
Number of subjects: 251

Group type: COMPARATOR
Intervention: ACDF (control)
Number of subjects: 251
Study: 18544952

Group type: EXPERIMENTAL
Intervention: PEG‐IFNalpha‐2a monotherapy
Number of subjects: 63
Study: 15780524

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5mg/day for 48 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (free-treatment)
Number of subjects: 116
Study: 12353080

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AR-C69931MX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 10333139

Group type: EXPERIMENTAL
Intervention: HBY 097 (non-nucleoside inhibitor of HIV-1 reverse transcriptase)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: HBY 097
Number of subjects: 2

Group type: COMPARATOR
Intervention: In vitro selection studies
Number of subjects: 2
Study: 9374447

Group type: EXPERIMENTAL
Intervention: Urodilatin (20 ng/kg/min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 1909603

Group type: EXPERIMENTAL
Intervention: Dihydroergokryptine 10 mg b.i.d.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dihydroergotamine 5 mg b.i.d. (controlled release)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neither treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dihydroergotamine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dihydroergokryptine
Number of subjects: 30
Study: 6238741

Group type: EXPERIMENTAL
Intervention: Postoperative use of special elastic bandages and oxyphenbutazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New traction treatment called auto‐traction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New mechanical device for tibial osteotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deyerle's technique for intracapsular hip fractures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New radiologic method for determining stability of tibial fractures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three to four weeks of immobilization for shoulder joint dislocations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of Colles' fracture with electromagnetic fields
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arthroscopic percutaneous meniscectomies
Number of subjects: 0
Study: 31215805

Group type: EXPERIMENTAL
Intervention: NaHCO3 (0.5 meq·kg body wt‐1·day‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: NaCl (0.5 meq·kg body wt‐1·day‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 120
Study: 30498836

Group type: EXPERIMENTAL
Intervention: 6-month interdisciplinary intervention based on physical exercise, Mediterranean diet advice, assessment of inadequate prescribing in polypharmacy patients and social assessment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard primary healthcare treatment
Number of subjects: 200
Study: 27824811

Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg b.i.d. (capsules)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265